Medline
Medline Inc.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$28.4B
Operating marginCalculated
7.8%
Net assets to total assetsCalculated
27.9%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★☆☆position among all companies
7.8%
Growth (revenue, 2-year average)
★★★★☆position among all companies
10.6%
Capital efficiency
★★★☆☆position among all companies
10.8%
Revenue and profit
Performance, financial position and capital allocation
Medline
Recent performance trends
Medline
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | Could not be retrieved | Could not be retrieved | US$23.2 billion | US$25.5 billion | US$28.4 billion |
| Operating income | Could not be retrieved | Could not be retrieved | US$1.2 billion | US$2.1 billion | US$2.2 billion |
| Net income | Could not be retrieved | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$1.2 billion |
| Total assets | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$36.0 billion | US$38.5 billion |
| Shareholders' equity | Could not be retrieved | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$10.7 billion |
| Net cash provided by (used in) operating activities | Could not be retrieved | Could not be retrieved | US$1.7 billion | US$1.8 billion | US$1.7 billion |
| Net cash provided by (used in) investing activities | Could not be retrieved | Could not be retrieved | US$-0.3 billion | US$-1.5 billion | US$-0.5 billion |
| Net cash provided by (used in) financing activities | Could not be retrieved | Could not be retrieved | US$-0.2 billion | US$-1.6 billion | US$0.4 billion |
| Cash and cash equivalents | Could not be retrieved | Could not be retrieved | Could not be retrieved | US$0.2 billion | US$1.9 billion |
Revenue scale in the same industry
Medline
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- 4 MedlineThis companyFY Dec 2025 US$28.4B
- 5 StrykerFY Dec 2025 US$25.1B
- 6 3MFY Dec 2025 US$24.9B
- … 37 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$1.9 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$0.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.7 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.0 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$19.3 billion | Consolidated | Disclosed |
| Non-controlling interests | US$8.5 billion | Consolidated | Disclosed |
| Net assets | US$10.7 billion | Consolidated | Disclosed |
| Net sales | US$28.4 billion | Consolidated | Disclosed |
| Operating income | US$2.2 billion | Consolidated | Disclosed |
| Net income | US$1.2 billion | Consolidated | Disclosed |
| Total assets | US$38.5 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$33.00 million | Consolidated | Disclosed |
| Operating margin | 7.8% | Consolidated | Calculated |
| Net assets to total assets | 27.9% | Consolidated | Calculated |
| Net margin | 4.1% | Consolidated | Calculated |
| Return on equity | 10.8% | Consolidated | Calculated |